Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TAEST16001
- Development stage
- Phase 2
- Lead developer
- Xiangxue Precision Medical Technology
- Modality
- Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
TAEST16001 is an autologous, affinity-enhanced, NY‑ESO‑1 antigen-specific, transduced T-cell receptor (TCR) therapy. Patient-derived (autologous) lymphocytes are genetically modified using a lentiviral vector to express a high-affinity engineered NY‑ESO‑1–specific TCR. The product is designed to target and kill tumor cells expressing the cancer-testis antigen NY‑ESO‑1 in HLA-A*02:01 positive patients. It is being developed primarily for advanced soft tissue sarcoma and has shown promising clinical activity with an overall response rate of approximately 41.7% in early-phase trials, with acceptable safety and no dose-limiting toxicities observed[2][3][4][5]. The developers include several Chinese academic and industry partners.
- Other names
- anti-NY‑ESO‑1 TCR LV-transduced autologous T cells
02
Targets
pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on TAEST16001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TAEST16001.